Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BT-11 in moderate to severe Crohn's disease
ISRCTN10684113Phase 2Completed
- Sponsor
- Landos Biopharma, Inc.
- Start
- May 2021
- Modality
- Small Molecules
01
Overview
Phase 2, randomised trial in Crohn's disease comparing BT-11 with Placebo (2 arms). Primary endpoint: Clinical remission rate. Started May 2021; status: completed.
02
Drugs
omilancor
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on ISRCTN10684113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN10684113.